SEC Form 4 · accession 0001104659-16-105521
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rahul Dhanda
Officer — SVP of Corporate Development
Period of report
Mar 14, 2016
Accepted (ET)
Mar 16, 2016 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 14, 2016 | M | 2,700 | $1.96 | A | 2,700 | D | |
| Common StockF1 | Mar 14, 2016 | S | 2,700 | $8.823 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.96 | Mar 14, 2016 | M | 2,700 | A | Apr 15, 2015 | Apr 15, 2021 | Common Stock | 2,700 | 13,770 | D |
Explanation of responses
- F1The price reported is a weighted average price. The shares were sold in multiple transactions at per share price ranging from $8.75 to $8.89. The reporting person undertakes to provide upon request the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.